Literature DB >> 9699733

Expression of mu-opiate receptor in human epidermis and keratinocytes.

P L Bigliardi1, M Bigliardi-Qi, S Buechner, T Rufli.   

Abstract

There is increasing evidence that neurotransmitters play a crucial role in skin physiology and pathology. The expression and production of proopiomelanocortin molecules such as beta-endorphin in human epidermis suggest that an opiate receptor is present in keratinocytes. In this paper we show that human epidermal keratinocytes express a mu-opiate receptor on both the mRNA level and the protein level. Performing polymerase chain reaction with cDNA libraries from human epidermal keratinocytes gave the polymerase chain reaction products of the expected length, which were confirmed as mu-opiate receptors by Southern blot analysis. Using in situ hybridization techniques with a specific probe for mu-opiate receptors we detected the receptor in human epidermis. There was a cytoplasmic expression in all layers of the epidermis, which was more distinct in the suprabasal layers. Immunohistochemistry using the mu-opiate receptor-specific antibody indicates that epidermis expresses protein as well, and that the protein level is more elevated in the basal layer. The correlation between the locations of both mRNA and protein expression in skin indicates that the mu-opiate receptor has not only been transcribed but also has a specific function. To prove a function of the receptor we performed a functional assay using skin organ cultures from human skin transplants. After 48 h incubation with Naloxone or beta-endorphin the expression of the mu-opiate receptor in epidermis was significantly downregulated compared with the control. These results show that a functional receptor indeed exists in human epidermis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9699733     DOI: 10.1046/j.1523-1747.1998.00259.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  23 in total

Review 1.  Peripheral opioid analgesia: clinical applications.

Authors:  Jochen Oeltjenbruns; Michael Schäfer
Journal:  Curr Pain Headache Rep       Date:  2005-02

Review 2.  [Potential applications and significance of peripheral opioid analgesia].

Authors:  J Oeltjenbruns; M Schäfer
Journal:  Schmerz       Date:  2005-10       Impact factor: 1.107

3.  Co-administration of δ- and μ-opioid receptor agonists promotes peripheral opioid receptor function.

Authors:  Cicely L Schramm; Christopher N Honda
Journal:  Pain       Date:  2010-12       Impact factor: 6.961

Review 4.  Management of itch in atopic dermatitis.

Authors:  Judith Hong; Joerg Buddenkotte; Timothy G Berger; Martin Steinhoff
Journal:  Semin Cutan Med Surg       Date:  2011-06

5.  Regulated proenkephalin expression in human skin and cultured skin cells.

Authors:  Andrzej T Slominski; Michal A Zmijewski; Blazej Zbytek; Anna A Brozyna; Jackie Granese; Alexander Pisarchik; Andre Szczesniewski; Desmond J Tobin
Journal:  J Invest Dermatol       Date:  2010-12-30       Impact factor: 8.551

Review 6.  Sensing the environment: regulation of local and global homeostasis by the skin's neuroendocrine system.

Authors:  Andrzej T Slominski; Michal A Zmijewski; Cezary Skobowiat; Blazej Zbytek; Radomir M Slominski; Jeffery D Steketee
Journal:  Adv Anat Embryol Cell Biol       Date:  2012       Impact factor: 1.231

7.  Opiates and the development of post-injury complications: a review.

Authors:  Martin G Schwacha
Journal:  Int J Clin Exp Med       Date:  2008-01-20

8.  Primary afferent neurons express functional delta opioid receptors in inflamed skin.

Authors:  Jill-Desiree Brederson; Christopher N Honda
Journal:  Brain Res       Date:  2015-04-22       Impact factor: 3.252

9.  Demethylating drugs as novel analgesics for cancer pain.

Authors:  Chi T Viet; Dongmin Dang; Yi Ye; Kentaro Ono; Ronald R Campbell; Brian L Schmidt
Journal:  Clin Cancer Res       Date:  2014-06-24       Impact factor: 12.531

10.  Topical Application of Loperamide/Oxymorphindole, Mu and Delta Opioid Receptor Agonists, Reduces Sensitization of C-fiber Nociceptors that Possess NaV1.8.

Authors:  Megan L Uhelski; Daniel Bruce; Rebecca Speltz; George L Wilcox; Donald A Simone
Journal:  Neuroscience       Date:  2020-08-25       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.